Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of AryoGen rFVIII-Fc vs Elocta in Severe Hemophilia A
NCT06137092Phase 3Completed
- Sponsor
- AryoGen Biopharma
- Start
- Jul 2023
- Primary completion
- Sep 2023
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 3 trial of efmoroctocog alfa in hemophilia A, sponsored by AryoGen Biopharma. Started Jul 2023; status: completed.
02
Drugs
efmoroctocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT06137092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06137092.